메뉴 건너뛰기
Medecine/Sciences
Volumn 27, Issue 3, 2011, Pages 249-251
Inhibition thérapeutique de mTOR dans la polykystose rénale autosomique dominante
Author keywords

[No Author keywords available]
Indexed keywords

MTOR PROTEIN, HUMAN; POLYCYSTIC KIDNEY DISEASE 1 PROTEIN; POLYCYSTIC KIDNEY DISEASE 2 PROTEIN; POLYCYSTIN; TARGET OF RAPAMYCIN KINASE;
EID: 79958745911     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/2011273249     Document Type: Article
Times cited : (1)
References (9)
  • 2
    • 34248350004 scopus 로고    scopus 로고
    • Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease
    • Leuenroth SJ, Okuhara D, Shotwell JD, et al. Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci USA 2007; 104: 4389-94.
    • (2007) Proc Natl Acad Sci USA , vol.104 , pp. 4389-4394
    • Leuenroth, S.J.1    Okuhara, D.2    Shotwell, J.D.3
  • 3
    • 38149005366 scopus 로고    scopus 로고
    • Vasopressin directly regulates cyst growth in polycystic kidney disease
    • Wang X, Wu Y, Ward CJ, et al. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008; 19: 102-8.
    • (2008) J am Soc Nephrol , vol.19 , pp. 102-108
    • Wang, X.1    Wu, Y.2    Ward, C.J.3
  • 4
    • 70350119696 scopus 로고    scopus 로고
    • Lanreotide reduces the volume of polycystic liver: A randomized, double-blind, placebo-controlled trial
    • Van Keimpema L, Nevens F, Vanslembrouck R, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009; 137: 1661-8.
    • (2009) Gastroenterology , vol.137 , pp. 1661-1668
    • Van Keimpema, L.1    Nevens, F.2    Vanslembrouck, R.3
  • 5
    • 33645769011 scopus 로고    scopus 로고
    • The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease
    • Shillingford JM, Murcia NS, Larson CH, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006; 103: 5466-71.
    • (2006) Proc Natl Acad Sci USA , vol.103 , pp. 5466-5471
    • Shillingford, J.M.1    Murcia, N.S.2    Larson, C.H.3
  • 6
    • 77956035166 scopus 로고    scopus 로고
    • Everolimus in patients with autosomal dominant polycystic kidney disease
    • Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 830-40.
    • (2010) N Engl J Med , vol.363 , pp. 830-840
    • Walz, G.1    Budde, K.2    Mannaa, M.3
  • 7
    • 77956029702 scopus 로고    scopus 로고
    • Sirolimus and kidney growth in autosomal dominant polycystic kidney disease
    • Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 820-9.
    • (2010) N Engl J Med , vol.363 , pp. 820-829
    • Serra, A.L.1    Poster, D.2    Kistler, A.D.3
  • 8
    • 79959342471 scopus 로고    scopus 로고
    • Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?
    • Canaud G, Knebelmann B, Harris PC, et al. Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: what is the appropriate serum level? Am J Transplant 2010; 10: 1701-6.
    • (2010) Am J Transplant , vol.10 , pp. 1701-1706
    • Canaud, G.1    Knebelmann, B.2    Harris, P.C.3
  • 9
    • 33751556669 scopus 로고    scopus 로고
    • Inhibiteurs de mTOR: Des antiprolifératifs pléiotropiques
    • Pallet N, Beaune P, Thervet E, et al. Inhibiteurs de mTOR: des antiprolifératifs pléiotropiques. Med Sci (Paris) 2006; 22: 947-52.
    • (2006) Med Sci (Paris) , vol.22 , pp. 947-952
    • Pallet, N.1    Beaune, P.2    Thervet, E.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.